tbuckley/cabot-search huggingface dataset:
Gladiator Games
Authors: Piyal Sen
Journal: BMJ (2006)

Nephronophthisis (NPHP), an autosomal-recessive cystic kidney disease, is the most frequent genetic cause of end-stage renal failure in children. NPHP types 1 and 4 are caused by mutations in <i>NPHP1</i> and <i>NPHP4</i>, encoding the proteins nephrocystin-1 and nephrocystin-4, respectively. Nephrocystin-1 and nephrocystin-4 are expressed in primary cilia of renal epithelial cells. <i>NPHP1</i> and <i>NPHP4</i> are highly conserved in <i>Caenorhabditis elegans</i>. However, this species does not have a kidney but an excretory system that consists of an excretory cell, an excretory gland cell, a duct cell, and a pore cell. Therefore, cell type–specific expression pattern and function of the nephrocystin homologs in <i>C. elegans</i> were of interest. Expression of green fluorescence protein fusion constructs that contain the <i>C. elegans</i> promoter regions for <i>nph-1</i> and <i>nph-4</i> was not found in the excretory system but in ciliated sensory neurons of the head (amphid neurons) and the tail in hermaphrodites (phasmid neurons) and males (sensory ray neurons). As the knockout phenotype for the <i>PKD</i> homologs <i>lov-1</i> and <i>pkd-2</i> shows impaired male mating behavior, RNAi knockdown animals were analyzed for this phenotype. A similar phenotype was found in the <i>nph-1</i> and <i>nph-4</i> RNAi knockdown animals compared with the <i>lov-1</i> and <i>pkd-2</i> knockout phenotype. Thus, it is suggested that renal cyst–causing genes may be part of a shared functional module, highly conserved in evolution. The NPHP homologs may be necessary for initial assembly of the cilium, whereas the polycystic kidney disease homologs may function as sensory transducers.
16. Diabetes Advocacy: <i>Standards of Medical Care in Diabetes—2019</i>
Journal: Diabetes Care (2019)

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Oral Contraception
Authors: T. Lovegrove
Journal: BMJ (1961)

<b>135</b> <h3><b>Introduction:</b></h3> Radiolabelled inhibitors of fibroblast activation protein (FAPI) have been introduced for PET imaging and may identify an early pathway leading to cardiac fibrosis. We describe molecular imaging patterns in patients early after acute myocardial infarction (AMI). <b></b> <h3><b>Methods:</b></h3> Cardiac magnetic resonance imaging (CMR), perfusion SPECT, and PET/CT with 68Ga-FAPI-46 (kindly provided by University of Heidelberg) were performed in 12 patients at 6-11 days after reperfused AMI. MRI defined cardiac function and extent of late gadolinium enhancement (LGE). SPECT polar maps were generated and compared to normal database for calculation of perfusion defect size. Regional standardized uptake values (SUV) were determined for FAPI, and quantitative polar maps defined the area of FAPI upregulation significantly elevated above blood pool (+ 2 standard deviations). Segmental analysis of FAPI-signal and LGE transmurality was performed using AHA 17-segment model. <b></b> <h3><b>Results:</b></h3> All patients exhibited regional FAP signal enrichment at the site of the infarct relative to blood pool (SUVpeak 5.8±1.6 vs. 2.1±0.5; p&lt;0.001). This signal was not observed in remote myocardium (1.5±0.3; p&lt;0.001) or other peripheral organs (liver, spleen, bone marrow, lungs). The extent of elevated myocardial FAP signal encompassed 56±8% of LV, significantly larger than perfusion defect (24±16%; p&lt;0.001). Mismatch between area of FAP upregulation and perfusion defect varied widely among individual patients (range 13-61%). Neither intensity nor extent of FAP signal correlated with available clinical variables, including measures of myocardial damage. CMR LGE was available in 10/12 patients. Expectedly, FAP signal was present in segments with transmural infarct (&lt;75% transmural LGE; 32/32) and 25-75% non-transmural infarct (57/60). However, even half of segments without significant LGE (39/78) also exhibited significant FAP signal, suggesting fibroblast activation in non-infarcted myocardium. <b></b><b>Conclusion:</b> Activation of fibroblasts markedly exceeds the hypoperfused infarct region in patients after AMI and early reperfusion therapy. The extent of this regional upregulation varies significantly among individuals, and underlying mechanisms as well as clinical consequences should be the subject of future studies. <b></b><b>Acknowledgements:</b> Supported by the Deutsche Forschungsgemeinschaft (KFO 311, JB, FMB) and the Fondation Leducq (Transatlantic Network ,,Immunofib“,FB)
Colored Covers
Authors: J. H. Rosenow
Journal: JAMA (1968)

<h3>To the Editor:—</h3> I completely disagree with Dr. Minsek (<b>204</b>:833, 1968), who complained how awful your covers are. I have found them interesting, stimulating, pleasant to look at, and a welcome change from the covers of most medical journals. Your captions connecting them to material inThe Journalare ingenious, diverting, and instructive.
Tolerability of 2-Weekly CHOP+Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis
Authors: Andrew Manson, Reem Karmali, Irene Dehghan-Paz, Eduardo Braun, Teresa O'Brien, Stephanie A. Gregory, Jamile M. Shammo, Melissa L Larson, Parmeswaran Venugopal
Journal: Blood (2010)
Treatment of Kasabach‐Merritt syndrome by embolisation of a giant liver hemangioma
Authors: A. Billio, N. Pescosta, C. Rosanelli, G.F. Zanon, P.G. Gamba, S. Savastano, P. Coser
Journal: American Journal of Hematology (2001)

We report the case of a 14-month-old child with Kasabach-Merritt Syndrome, due to a giant liver hemangioma. The therapeutic approach consisted of peripheral transcatheter embolisation of the right hepatic artery with Ivalon microspheres without the addition of thrombogenic material. This procedure brought to a sensible permanent reduction of the size of the liver hemangioma with normalisation of the previous altered coagulation parameters after 6 years of follow-up. Am. J. Hematol. 66:140–141, 2001. © 2001 Wiley-Liss, Inc.
Health Issues in Ethnic Minorities: Awareness and Action
Authors: M Memon, F Abbas, M Khaonolakar, J Dixon, I Singh
Journal: Journal of the Royal Society of Medicine (2002)

A key issue in health provision is the approach to health inequalities. In the UK, black and ethnic minority populations are disadvantaged in this respect. We obtained annual/public health reports from 13 health authorities (HAs) and 22 primary care trusts/groups (PCT/Gs) serving conurbations with large black and ethnic minority populations, and examined them for mention of special health issues for these groups and the action being taken. 22 of the 35 reports referred to such issues but only 17 referred to special initiatives; the most frequently mentioned were diabetes and coronary heart disease. We recommend that HAs and PCT/Gs serving large black and ethnic minority populations state specifically in their annual reports their awareness of health-equality issues and the action being taken to address them.
Contact dermatitis due to methylprednisolone
Authors: R. J. Coskey
Journal: JAMA (1967)

<h3>To the Editor:—</h3> I have seen and examined more than 300 transvestites and transsexuals during the past 14 years, and am at present engaged in active research on this problem with a number of collaborators, under a grant from the Erickson Educational Foundation. I have just published the first medical book on the subject,<i>The Transsexual Phenomenon</i>(Julian Press, New York). Dr. Hastings has given a clear and comprehensive summary, especially as to the management of transsexualism (<b>197</b>:599, 1966). Dr. Barker is right in differentiating transvestism from transsexualism (<b>198</b>:488, 1966), but he did not emphasize the fact that transvestism can be merely a symptom of transsexualism, which is a psychopathological condition, based on a disturbance of gender role orientation. According to recent animal experiments by Seymour Levine and Roger Gorski, transsexualism may indeed have a neuro-endocrine, prenatal origin, with transvestism as its most frequent symptom in later life.
Clinical practice guidelines. Does the cookbook have enough recipes?
Authors: W. W. Parmley
Journal: JAMA (1994)

This issue ofThe Journal<sup>1</sup>contains the first of a series of four articles to be published in<i>JAMA</i>that summarize selected aspects of a much larger document, "Heart Failure: Evaluation and Care of Patients With Left Ventricular Systolic Dysfunction," which was published as a clinical practice guideline by the US Department of Health and Human Services.<sup>2</sup> See also p 1361. With the support of staff from RAND, a panel of 16 individuals knowledgeable in various aspects of heart failure authored the larger document, while selected members have authored the four subsections accepted for publication in<i>JAMA</i>. The potential value of these and other guidelines is that the authors have carefully evaluated the world's literature, with particular emphasis on well-controlled trials, as the basis for decision making. In the original document, a laudable attempt was made to classify the scientific validity of each study and conclusion using seven
Error in Results
Journal: JAMA Network Open (2020)

In the Original Investigation titled "Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic," 1 published August 4, 2020, there were errors in the Figure and Results sections.The percentage of patients who were included in the COVID-19 period was 7.2%.The denominators given in the distribution of women with pancreatic cancer has been changed to 16 248 and 1546 to account for 21 patients who did not have gender information.In the Figure, an additional column was added to represent data on esophageal cancer, and the dates of the weeks in the periods examined were adjusted by 1 day.This article has been corrected. 1
LETTER FROM NEW YORK.
Authors: None P. B. P.
Journal: JAMA (1891)

<h3>LETTER FROM NEW YORK.</h3> (FROM OUR OWN CORRESPONDENT.) New York Physicians and the Koch Lymph—Dr. J. H. Tyndale and the Treatment of Tuberculosis by Inoculation—Statistics of Phthisis and Pneumonia—Dr. Oliver Wendell Holmes on Academies—The State Commissian on Lunacy—A History of Legislation for the Insane in the State of New York—Public Baths for Winter Use—Miscellaneous Gleanings. During the past month quite a number of New York physicians, the most of them acting as representatives of medical schools and hospitals, have gone to Berlin to made a personal study of the inoculation method of Koch. The first consignments here of "lymph" from Germany were received about the same time at the Hospital for Ruptured and Crippled, St. Luke's Hospital and Mount Sinai Hospital, and the physicians of these institutions have been assiduously experimenting with it it upon appropriate cases. At the first-named hospital the patients treated have been principally children suffering from
Heterophilic Type II Cadherins Are Required for High-Magnitude Synaptic Potentiation in the Hippocampus
Authors: Raunak Basu, Xin Duan, Matthew R. Taylor, E. Anne Martin, Shruti Muralidhar, Yueqi Wang, Luke Gangi-Wellman, Sujan C. Das, Masahito Yamagata, Peter J. West, Joshua R. Sanes, Megan E. Williams
Journal: Neuron (2018)

(Neuron 96, 160–176; September 27, 2017) In the original publication of the article, x axis labels for LTP time course summaries in the following figures were mistakenly labeled in seconds when they should be labeled in minutes: Figures 1M, 3A, 3C, 3G, 3I, 6A, 6C, 6E, 6G, 7A, 7C, 7E, 7G, and Figures S5B and S5D. The data are unaffected and the authors apologize for the errors.Figure 1CA1 Excitatory Synapses Have Layer-Specific Properties (original)View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 3Cadherin-9 Regulates High-Magnitude LTP in CA1 SO (corrected)View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 3Cadherin-9 Regulates High-Magnitude LTP in CA1 SO (original)View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 6Cadherins-6 and –10 Are Required for High-Magnitude LTP in CA1 SO (corrected)View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 6Cadherins-6 and –10 Are Required for High-Magnitude LTP in CA1 SO (original)View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 7Cadherins-6, –9, and –10 Are Required for Picrotoxin-Induced High-Magnitude LTP in SR (corrected)View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 7Cadherins-6, –9, and –10 Are Required for Picrotoxin-Induced High-Magnitude LTP in SR (original)View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure S5(corrected)View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure S5(original)View Large Image Figure ViewerDownload Hi-res image Download (PPT) Heterophilic Type II Cadherins Are Required for High-Magnitude Synaptic Potentiation in the HippocampusBasu et al.NeuronSeptember 27, 2017In BriefBasu et al. demonstrate that different synaptic layers of hippocampal CA1 neurons have distinct synaptic potentiation properties and three heterophilic cadherins, cadherins-6, -9, and -10, are required for normal mushroom spine density and high-magnitude LTP specifically in CA1 basal dendrites. Full-Text PDF Open Archive
I qualified in 1999 and went straight into a vocational training scheme after my house officer year. I have worked as a salaried or locum GP since, doing occasional sessions as a clinical assistant in an accident and emergency department. I would like to pursue a career in ophthalmology and am looking for a senior house officer (SHO) post in this field. Based on my years since qualifying, I am equivalent to a year six SHO. What level of the pay scale I will slot into for basic pay? Am I …
Authors: Sarah Burnett
Journal: BMJ (2006)

Have a career or related problem that needs answering? Can9t find the right person to point you in the right direction? Log on to the Advice Zone for reliable medical careers advice. You can post a question or see if one of our 300 advisers has already answered a similar question. Here is a selection of questions and answers posted on the site. <b>www.bmjcareers.com/advicezone</b>
Wind
Authors: William K. Beatty
Journal: JAMA (1974)

<h3>To the Editor.—</h3> Several important types of winds were omitted from your list. The strong blast off the ocean on a deserted Delaware beach, for example, that helped me, as a youngster gain some feeling for the force of nature and the smallness of mankind. Or, of a more general occurrence, the blast of hot air that is found in so many meetings. The section on the<i>Foehn</i>lacked a musical item, the psychological hit of a few years back, "All Alone by the Tele<i>Foehn</i>."
Erroneous Cohort Totals in Abstract
Journal: JAMA Oncology (2019)

Philip J. Lupo, PhD; Jeremy M. Schraw, PhD; Tania A. Desrosiers, PhD; Wendy N. Nembhard, PhD; Peter H. Langlois, PhD; Mark A. Canfield, PhD; Glenn Copeland, MBA; Robert E. Meyer, PhD; Austin L. Brown, PhD; Tiffany M. Chambers, MPH; Pagna Sok, MPH; Heather E. Danysh, PhD; Susan E. Carozza, PhD; Saumya D. Sisoudiya, BS; Susan G. Hilsenbeck, PhD; Amanda E. Janitz, PhD; Matthew E. Oster, MD, MPH; Angela E. Scheuerle, MD; Joshua D. Schiffman, MD; Chunqiao Luo, MS; Amir Mian, MD; Beth A. Mueller; Chad D. Huff, PhD; Sonja A. Rasmussen, MD, MS; Michael E. Scheurer, PhD; Sharon E. Plon, MD, PhD
Adults Join Kids in e-Cigarette Use
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prevention of impairment among residents in training
Authors: B. Blackwell
Journal: JAMA (1986)

The rigors of residency training and the rites of passage endured between graduation and practice have been cataloged over the years in a variety of biographical and anecdotal formats, including books that range from scholarly surveys<sup>1</sup>to best-selling novels.<sup>2</sup>Norman Cousins'<sup>3</sup>earlier editorial on this topic identified internship as "the weakest link in the entire chain of physician training" and provoked a lively debate in the correspondence columns ofThe Journalregarding the degree to which the experience provided legitimate preparation for practice or was a hazardous form of hazing. The national survey by Smith and co-workers4 published in this issue ofThe Journalprovides a much needed source of information with which to temper the debate. Their major finding is that 0.9% of internal medicine residents take a leave of absence because of emotional impairment during their training, declining from a peak of 1.4% during internship to
Leukemia patients to be given varicella vaccine
Authors: P. Gunby
Journal: JAMA (1982)

Varicella vaccine, still experimental in this country, is being used in an effort to protect leukemia patients from potentially fatal chickenpox. The project eventually will involve 500 patients with acute lymphocytic leukemia who never have had chickenpox and lack antibodies to the varicella-zoster virus. An additional group of leukemia patients— those who have survived natural varicella infection without vaccination—are being recruited as controls. The National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Md, which is supporting the study, estimates that up to 7% of immunosuppressed leukemia patients who contract varicella will die. That estimate is largely based on treatment of 77 young cancer patients at St. Jude's Children's Research Hospital, Memphis. Sixty of these patients were immunosuppressed when they developed varicella; four died (<i>Pediatrics</i>1975;56:388-397). Among presumably healthy persons, the varicella death-to-case ratio recently in this country has been 6.7/10,000, according to data compiled by Stephen R. Preblud, MD,
Abstract 4656: TRAF1 is critical for regulating the BRAF/MEK/ERK pathway in non-small cell lung carcinogenesis
Authors: Qiushi Wang, Tianshun Zhang, Ge Gao, Ann Bode, Zigang Dong
Journal: Cancer Research (2019)

Abstract Tumor necrosis factor receptor (TNFR)-associated factor 1 (TRAF1) is a unique TRAF protein that can interact directly or indirectly with multiple TNFR family members, regulatory proteins, kinases, and adaptors that contribute to its diverse functions in specific tissues. However, the role of TRAF1 in non-small cell lung cancer (NSCLC) remains unknown. In this study, we report that TRAF1 is overexpressed in human lung cancer cells and tissues. TRAF1 expression level inversely correlated with patient survival probability. Loss of TRAF1 decelerated tumor invasion in a urethane-induced lung carcinogenesis mouse model. Furthermore, TRAF1 expression affected TRAF2-mediated BRAF Lys48-linked ubiquitination, which was followed by the inhibition of growth and differentiation, and the induction of death in lung cancer cells. Overall, our work suggests that TRAF1 plays a novel role in the regulation of the BRAF/MEK/ERK signaling pathway in NSCLC and offers a candidate molecular target for lung cancer prevention and therapy. Citation Format: Qiushi Wang, Tianshun Zhang, Ge Gao, Ann Bode, Zigang Dong. TRAF1 is critical for regulating the BRAF/MEK/ERK pathway in non-small cell lung carcinogenesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4656.
Factors predicting low patient accrual in cancer clinical trials
Authors: Caroline Bennette
Journal: JNCI Journal of the National Cancer Institute (2015)

Factors predicting low patient accrual in cancer clinical trialsNearly one in four publicly sponsored cancer clinical trials fail to enroll enough participants to draw valid conclusions about treatments or techniques.Such trials represent a waste of scarce human and economic resources and contribute little to medical knowledge.Although many studies have investigated the perceived barriers to accrual from the patient or provider perspective, very few have taken a trial-level view and asked why certain trials are able to accrue patients faster than expected while others fail to attract even a fraction of the intended number of participants.According to a study
Junior Hospital Staff Contract
Authors: A. P. Brooks, J. F. Martin, D. Kirk, J. Tomich, A. J. Keogh, D. J. E. Farrand, I. Taylor, G. P. Mulley, J. Gopel, I. R. Edwards, J. F. Harrison, A. S. Ward, J. W. Ward, S. L. Steadman, D. C. Cumberland, J. S. Lilleyman, L. Rushbrook, C. G. Koffman, D. W. Bullock, V. E. Mitchell, A. Goodfellow, J. O'Callaghan
Journal: BMJ (1975)
In This Issue
Journal: Journal of Clinical Investigation (2010)

MKP-3 promotes hepatic glucose productionThe excessive hepatic gluconeogenesis that occurs in insulin-resistant individuals is a key factor in their development of hyperglycemia and progression to type 2 diabetes mellitus.Recent in vitro data indicate that MAPK phosphatase-3 (MKP-3) promotes the transcription of genes encoding proteins involved in gluconeogenesis.Wu and colleagues therefore set out to investigate whether MKP-3 has similar effects in vivo (3901-3911).Initial analysis indicated that MKP-3 expression is elevated in the liver of diet-induced obese mice.Consistent with these data and the hypothesis that MKP-3 promotes gluconeogenesis, overexpression of MKP-3 in lean mice increased fasting blood glucose levels, whereas knockdown of MKP-3 expression in both lean and obese mice decreased fasting blood glucose levels.Further analysis revealed that MKP-3 induced the transcription of genes encoding proteins involved in gluconeogenesis by dephosphorylating forkhead box O1 (FOXO1), which promoted its translocation to the nucleus and subsequent induction of PPARγ coactivator-1α (Pgc1a) transcription.As these data indicate that MKP-3 has a key role in promoting hepatic gluconeogenesis in vivo in mice, the authors suggest that it might provide a new therapeutic target for the treatment of obesity-related hyperglycemia and type 2 diabetes mellitus.